Navigation Links
Wyler Subpial Transector

ProductsWyler Subpial Transector
Company Ad-Tech Medical
Item Wyler Subpial Transector
Features 
  • Lightweight, disposable handle
  • Three 0.55 mm diameter tip styles (blunt, sharp, and blade)
  • Sterile; single-use only
  • Description Multiple Subpial Transection (MST) is a surgical technique designed to treat epilepsy when the seizure focus is in a cortical area that cannot be surgically resected without causing an unacceptable neurological deficit. In this technique, fine parallel cuts are made in the cortical surface to disrupt the initial spread of the seizure discharge without compromising the vertical organization of the cortex. Ad-Techs Wyler Subpial Transector offers you three choices in tips (blunt, sharp & blade), which comes with a disposable handle.
    Info Ad-Tech Medical
    Customer Service: (800) 776-1555
    Web site: http://www.adtechmedical.com

    Related medicine products :

    1. Ad-Tech/Wyler Subdural Strip & Grid Electrodes
    ZapICD
    ZapBill Anesthesia
    WardWatch v3.1.1
    MedCalc 3000
    Medicine Products:
    (Date:12/2/2009)...linical trial presented today at the annual meetin...NA) provide the first strong evidence of the benef...ense breasts who are at elevated risk for breast c...s highly sensitive in depicting early breast cance...ound in addition to mammography significantly impr...
    (Date:12/1/2009)...RNewswire/ -- Reportlinker.com announces that a ne...ogue: ,, The Future of Central Nervous System ...Competitive Benchmarking, Product Pipeline and Dea...166814/The-Future-of-Central-Nervous-System-Diseas...tive-Benchmarking-Product-Pipeline-and-Deals-Analy...
    (Date:12/1/2009)...wire-USNewswire/ -- The Kerlan Jobe Orthopaedic Cl... agreed to pay the United States $3 million to set... from HealthSouth Corporation, the Justice Departm...olves allegations that HealthSouth paid kickbacks ... donations to the Kerlan Jobe Foundation, loan for...
    (Date:12/1/2009)...rths more likely, British study finds , ,...en who are poor are more likely to deliver a very ... both groups typically receive equal care, a new B...er research team said their findings show the need...mic status and preterm birth. , For the study, ...
    (Date:12/1/2009)...ation Changes Name to HealthHIV , ...ation, one of the largest national HIV non-profit ...nd launching a new website. The announcement on Wo...n to promote the organization’s new vision a...uo;HealthHIV clearly, quickly and easily states ou...
    Breaking Medicine News(10 mins):Health News:Annual screening with breast ultrasound or MRI could benefit some women 2Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 14Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 15Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 16Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 17Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 18Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 19Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 20Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 21Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 22Health News:Los Angeles' Kerlan Jobe Orthopaedic Clinic Pays $3 Million to Settle Kickback Allegations 2Health News:More Preemies Born Among the Poor 2Health News:National HIV Non-Profit Announces New Name 2
    ... cancer is currently one of the most common male c...h in men.// Findings from a recent study suggests ... The study, conducted in a mouse model of human p...ke, growth-factor-driven pathway present in prosta...
    ...udy shows that low low-density lipoprotein, also k... by 10 percent // thereby improving the relative a...et that includes between eight and 10 walnuts a da...betes. A team of dieticians developed individua...
    ... ablation is a non-surgical technique used to elim...se abnormal heartbeats. // Researchers now say tha...atrial fibrillation a type of irregular heart rhyt...re who were undergoing catheter ablation for atria...
    ...ion to being at-risk for various health conditions... being accurately diagnosed // during medical imag...y obesity can limit the ability and accuracy of im... nearly doubled from 0.10 percent to 0.19 percent ...
    ... study shows chronic back pain shrinks the brain ...he degeneration of 10 to 20 years of aging.// ...tomated analysis techniques, researchers compared ...in for more than one year. The study showed tha...
    ...udy suggests young people are more likely to becom...form of a gene // that helps clear nicotine out of... CYP2A6 gene were about three-times more likely to...igarettes. In a study, carried out among seventh g...
    Other Medicine News:
    (Date:12/1/2009)...swire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex...loper of vaccines and therapeutics for the prevent...d today that it has retained the services of an in...o run CEL-SCI,s upcoming Phase III clinical trial ...Company,s lead product candidate, Multikine®....
    (Date:12/1/2009)...PRNewswire/ -- Sleep Solutions®, Inc. (SSI), ...esting and evaluation of sleep-disordered breathin....D., as its chief executive officer. Hassett was ...ng its growth from a $250 million healthcare holdi...total population health, and its subsequent sale f...
    (Date:12/1/2009)... 1 Siemens Hearing Instruments, I...al manufacturer of hearing instruments, announced ...nal,s Sound Beginnings program. The alliance will ... of the renewed partnership, Siemens is expanding ...ng instruments to both children and young adults, ...
    Breaking Medicine Technology:CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 2CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 3Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 2Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 3Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 3Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 1Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 2Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 3Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 4Long Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax 28R 29 Brain 5631 5Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 1Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 3Shire Targets Fourth Quarter Filing of BLA for REPLAGAL 28R 29 for Fabry Disease With U S FDA 5629 4Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 1Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 2Vestara Joins National Health Organization Practice Greenhealth to Further Support Environmental Practices 59887 3